Market Cap
$1.1B
VOR
Vor Biopharma Inc.
$18.69 ▲ +3.49%
Prev close $18.06Market cap$1.1B
ConsensusStrong Buy
12-mo target$39.00 (+108.7%)
▲ Bullish
Analyst conviction 9/10
21 New Institutional Positions9 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on VOR right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (85%)
Inst. Holders
50 funds
Inst. Value
$388.0M
Inst. Activity
21 buys / 9 sells
Insider Activity
$0.00 buy / $49.4M sell
Insider Net $
-$49.4M
SEC Reports
6
Press Releases
3
Price chart 30d -22.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 contract
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48
Aug 24, 2026 Insider
Aug 11, 2026 SEC RA CAPITAL MANAGEMENT, L.P. acquired via exercise 1,500 shares
10%+ Owner @ $3.74 ($5.6K)
Vor Bio reported Q2 2026 financial results with net loss of $62.8M, cash of $466.1M (plus $48.4M from July ATM sales), a
PRESS-RELEASE — Impact 3/10
Jul 16, 2026 Insider
RA CAPITAL MANAGEMENT, L.P. acquired via exercise 2,100,000 shares
10%+ Owner @ $0.002000 ($4.2K)
Jul 16, 2026 Insider
Jul 9, 2026 SEC RA CAPITAL MANAGEMENT, L.P. acquired via exercise 2,100,000 shares
10%+ Owner @ $5.00 ($10.5M)
David Zaccardelli filed a Form 3 initial statement of beneficial ownership with Vor Biopharma Inc. on July 9, 2026, repo
3 — Impact 2/10
Jun 30, 2026 Inst.
FMR LLC — DOUBLED
4,932,149 shares ($90.8M)
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
3,468,107 shares ($63.8M)
Analyst ratings buy % +6.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
85% rate it Buy or better · 13 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 12, 2026 | Wedbush | MAINTAIN | Neutral | 57% |
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 14, 2026 | Wedbush | MAINTAIN | Neutral | 57% |
| Apr 15, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Aug 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Jul 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Jun 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| May 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Apr 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Mar 1, 2026 | 4 | 5 | 2 | 0 | 0 | 82% | |
| Feb 1, 2026 | 4 | 5 | 2 | 0 | 0 | 82% |
Price targets
Where 8 covering analysts think VOR trades over the next 12 months.
$39.00 +108.7% upside Strong Buy
Current$18.69 Low$27.00 Median$40.00 High$50.00 8 analysts
$27.00$50.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 6 neutral · avg impact 2.7/10.Plus 3 press releases.
NEUTRALPRESS-RELEASE3/10
Vor Bio reported Q2 2026 financial results with net loss of $62.8M, cash of $466.1M (plus $48.4M fro
Aug 11, 2026
NEUTRAL32/10
David Zaccardelli filed a Form 3 initial statement of beneficial ownership with Vor Biopharma Inc. o
Jul 9, 2026
NEUTRALINST-CLUSTER3/10
Five mega-passive institutional investors (Vanguard, BlackRock, State Street, Fidelity, Morgan Stanl
Jun 11, 2026
NEUTRALEFFECT3/10
Vor Biopharma's S-3 registration statement (File No. 333-295346) became effective on May 6, 2026, en
May 7, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
contract
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48
Aug 31, 2026
short_interest_report
Short Interest: VOR up 4% to 7.7M shares
Settlement 2026-08-31 | Days to cover: 10.37 | ≈12.96% of shares outstanding (est.)
Aug 14, 2026
ftd
FTD: VOR — 45,043 shares ($1.0M) failed to deliver
Settlement: 20260814, Price: $23.29, FTD Value: $1,049,051.47, VOR BIOPHARMA INC COM NEW
Aug 11, 2026
earnings
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27
Aug 10, 2026
earnings_calendar
VOR Q2 2026 Earnings Scheduled — 2026-08-10
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.72 | $-0.72–$-0.72 | 99.4% | +0.0% | 1↑ 1↓ | $0.0B | 1 |
| Next Q | $-0.77 | $-0.77–$-0.77 | -100.3% | +0.0% | 1↑ 1↓ | $0.0B | 1 |
| Current FY | $-6.53 | $-6.53–$-6.53 | 90.7% | +0.0% | 1↑ 1↓ | $0.0B | 1 |
| Next FY | $-3.82 | $-4.50–$-2.93 | 41.6% | -0.1% | 1↑ 1↓ | $0.0B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.720 | — |
| 7d ago | $-0.720 | — |
| 30d ago | $-0.720 | — |
| 60d ago | $-0.768 | +0.048 |
| 90d ago | $-0.768 | +0.048 |
Institutional ownership
Which big funds own VOR (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $388.0M total value (21,072,934 shares) as of 2026-Q2. Top holders: FMR, BlackRock,, STATE. Net buying activity: 21 institutions added/increased vs 9 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 4,932,149 | $90.8M | 23.4% | DOUBLED +220.3% |
| BlackRock, Inc. | 3,468,107 | $63.8M | 16.5% | DOUBLED +336.4% |
| STATE STREET CORP | 2,616,336 | $48.2M | 12.4% | DOUBLED +133.9% |
| RA CAPITAL MANAGEMENT, L.P. | 2,402,095 | $44.2M | 11.4% | TRIM -55.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,084,328 | $38.4M | 9.9% | ADD +45.4% |
| GEODE CAPITAL MANAGEMENT, LLC | 1,062,469 | $19.6M | 5.0% | DOUBLED +210.1% |
| UBS Group AG | 493,278 | $9.1M | 2.3% | ADD +67.2% |
| MILLENNIUM MANAGEMENT LLC | 428,067 | $7.9M | 2.0% | ADD +65.5% |
| Woodline Partners LP | 379,723 | $7.0M | 1.8% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 340,364 | $6.3M | 1.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FMR LLC | DOUBLED | 1,539,670 | 4,932,149 | +220.3% | $90.8M |
| BlackRock, Inc. | DOUBLED | 794,759 | 3,468,107 | +336.4% | $63.8M |
| STATE STREET CORP | DOUBLED | 1,118,458 | 2,616,336 | +133.9% | $48.2M |
| RA CAPITAL MANAGEMENT, L.P. | TRIM | 5,404,998 | 2,402,095 | -55.6% | $44.2M |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | 1,433,280 | 2,084,328 | +45.4% | $38.4M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 342,573 | 1,062,469 | +210.1% | $19.6M |
| MILLENNIUM MANAGEMENT LLC | ADD | 258,587 | 428,067 | +65.5% | $7.9M |
| GOLDMAN SACHS GROUP INC | ADD | 261,891 | 328,892 | +25.6% | $6.1M |
| NORTHERN TRUST CORP | DOUBLED | 64,549 | 328,742 | +409.3% | $6.1M |
| VANGUARD FIDUCIARY TRUST CO | ADD | 185,511 | 300,704 | +62.1% | $5.5M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 28 transactions. Net -$49.4M — $0.00 bought, $49.4M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 24, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | EXERCISE | 1,500 | $3.74 | $5.6K |
| Jul 16, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | EXERCISE | 2,100,000 | $0.002000 | $4.2K |
| Jul 16, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | EXERCISE | 2,100,000 | $5.00 | $10.5M |
| Jul 16, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | SELL | 213 | $19.75 | $4.2K |
| Jul 7, 2026 | ZACCARDELLI DAVID | Director | AWARD | 42,658 | — | — |
| Jun 11, 2026 | Levin Andrew David | Director | AWARD | 57,162 | — | — |
| Jun 11, 2026 | Kalir Erez | Director | AWARD | 57,162 | — | — |
| Jun 11, 2026 | Beckman Daniella | Director | AWARD | 53,283 | — | — |
| Jun 11, 2026 | Cumbo Alexander | Director | AWARD | 56,345 | — | — |
| Jun 11, 2026 | Joustra Wouter | Director | AWARD | 57,162 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for VOR.
Shares short
7,904,520
Settlement Sep 15, 2026
Change vs prior
+3.1%
Semi-monthly cycle
Days to cover
11.1
At avg daily volume
Of shares outstanding
≈13.4%
Estimate — not % of float
All VOR filing & press-release reports (9)
- PRESS-RELEASE reportAug 11, 2026
- 3 reportJul 9, 2026
- INST-CLUSTER reportJun 11, 2026
- PRESS-RELEASE reportJun 8, 2026
- EFFECT reportMay 7, 2026
- S-3 reportApr 27, 2026
- DEFA14A reportApr 27, 2026
- PRESS-RELEASE reportMar 27, 2026
- PRESS-RELEASE reportMar 23, 2026